Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antidepressant-like effect in the rat forced swim test

Brain Research Bulletin

Volumn 85, Issue 3-4, 2011, Pages 153-157

  Xing, Bo ^a,b,c   Zhao, Yan ^a,b   Zhang, Hui ^c   Dang, Yonghui ^a,b   Chen, Teng ^a,b   Huang, Jingfeng ^a,b   Luo, Qi ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^c Xi'an Mental Health Center   (China)

Author keywords

Antidepressant; Forced swimming test; Microinjection; Valproic acid; Ventrolateral orbital cortex

Indexed keywords

FLUOXETINE; PENICILLIN G SODIUM; PENTOBARBITAL; SODIUM CHLORIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; FORCED SWIMMING TEST; INFUSION; LOCOMOTION; MALE; MICROINJECTION; NONHUMAN; ORBITAL CORTEX; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REPEATED DRUG DOSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; MALE; MICROINJECTIONS; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SWIMMING; VALPROIC ACID;

EID: 79957808677     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.03.007     Document Type: Article

References (51)

1. Baldessarini R.J. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 2002, 16:721-729.
2. Ballmaier M., Toga A.W., Blanton R.E., Sowell E.R., Lavretsky H., Peterson J., Pham D., Kumar A. Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRIbased parcellation of the prefrontal cortex. Am. J. Psychiatry 2004, 161:99-108.
3. Berman R.M, Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
4. Blendy J.A. The role of CREB in depression and antidepressant treatment. Biol. Psychiatry 2006, 59:1144-1150.
5. Coffey C.E., Wilkinson W.E., Weiner R.D., Parashos I.A., Djang W.T., Webb M.C., Figiel G.S., Spritzer C.E. Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study. Arch. Gen. Psychiatry 1993, 50:7-16.
6. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
7. Cryan J.F., Page M.E., Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl) 2005, 182:335-344.
8. Davis L.L., Kabel D., Patel D., Choate A.D., Foslien-Nash C., Gurguis G.N., Kramer G.L., Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull. 1996, 32:647-652.
9. Drevets W.C. Neuroimaging studies of mood disorders. Biol. Psychiatry 2000, 48:813-829.
10. Drevets W.C., Price J.L., Simpson J.R., Todd R.D., Reich T., Vannier M., Raichle M.E. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997, 386:824-827.
11. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
12. e Silva J.A. Overview of the field. Metabolism. 2005, 54:5-9.
13. Einat H., Yuan P., Gould T.D., Li J., Du J., Zhang L., Manji H.K., Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 2003, 23:7311-7316.
14. Emrich H.M., von Zerssen D., Kissling W., Moller H.J., Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980, 229:1-16.
15. Esclapez M., Campistron G., Trottier S. Immunocytochemical localization and morphology of GABA-containing neurons in the prefrontal and frontoparietal cortex of the rat. Neurosci. Lett. 1987, 77:131-136.
16. Gourley S.L., Wu F.J., Kiraly D.D., Ploski J.E., Kedves A.T., Duman R.S., Taylor J.R. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol. Psychiatry 2008, 63:353-359.
17. Hayes S.G. Long-term use of valproate in primary psychiatric disorders. J. Clin. Psychiatry 1989, 50(Suppl):35-39.
18. Hennings E.C., Kiss J.P., Vizi E.S. Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Brain Res. 1997, 759:292-294.
19. Huo F.Q., Wang J., Li Y.Q., Chen T., Han F., Tang J.S. GABAergic neurons express mu-opioid receptors in the ventrolateral orbital cortex of the rat. Neurosci. Lett. 2005, 382:265-268.
20. Krystal J.H., Sanacora G., Blumberg H., Anand A., Charney D.S., Marek G., Epperson C.N., Goddard A., Mason G.F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 2002, 7(Suppl 1):S71-80.
21. Lambert P.A., Carraz G., Borselli S., Bouchardy M. Dipropylacetamide in the treatment of manic-depressive psychosis. Encephale 1975, 1:25-31.
22. Layer R.T., Popik P., Olds T., Skolnick P. Antidepressant-like actions of the polyamine site NMDA antagonist, eliprodil (SL-82.0715). Pharmacol. Biochem. Behav. 1995, 52:621-627.
23. Lenkey N., Karoly R., Kiss J.P., Szasz B.K., Vizi E.S., Mike A. The mechanism of activity-dependent sodium channel inhibition by the antidepressants fluoxetine and desipramine. Mol. Pharmacol. 2006, 70:2052-2063.
24. Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 1999, 58:31-59.
25. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
26. Monti B., Polazzi E., Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr. Mol. Pharmacol. 2009, 2:95-109.
27. Murray C.J, Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
28. Passingham R.E., Toni I., Rushworth M.F. Specialisation within the prefrontal cortex: the ventral prefrontal cortex and associative learning. Exp. Brain Res. 2000, 133:103-113.
29. Pirker S., Schwarzer C., Wieselthaler A., Sieghart W., Sperk G. GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000, 101:815-850.
30. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
31. Princivalle A.P., Pangalos M.N., Bowery N.G., Spreafico R. Distribution of GABA(B(1a)), GABA(B(1b)) and GABA(B2) receptor protein in cerebral cortex and thalamus of adult rats. Neuroreport 2001, 12:591-595.
32. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry 2000, 48:766-777.
33. Rajkowska G., Miguel-Hidalgo J.J., Wei J., Dilley G., Pittman S.D., Meltzer H.Y., Overholser J.C., Roth B.L., Stockmeier C.A. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 1999, 45:1085-1098.
34. Redrobe J.P., Bourin M. Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl) 1999, 141:370-377.
35. Rostock A., Hoffmann W., Siegemund C., Bartsch R. Effects of carbamazepine, valproate calcium, clonazepam and piracetam on behavioral test methods for evaluation of memory-enhancing drugs. Methods Find. Exp. Clin. Pharmacol. 1989, 11:547-553.
36. Sanacora G, Mason G.F., Krystal J.H. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit. Rev. Neurobiol. 2000, 14:23-45.
37. Sanacora G., Mason G.F., Rothman D.L., Hyder F., Ciarcia J.J., Ostroff R.B., Berman R.M., Krystal J.H. Increased cortical GABA concentrations in depressed patients receiving ECT. Am. J. Psychiatry 2003, 160:577-579.
38. Sanacora G., Mason G.F., Rothman D.L., Krystal J.H. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am. J. Psychiatry 2002, 159:663-665.
39. Sanacora G., Saricicek A. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. CNS Neurol. Disord. Drug Targets 2007, 6:127-140.
40. Schroeder F.A., Lin C.L., Crusio W.E., Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry 2007, 62:55-64.
41. Shirayama Y, Chen A.C., Nakagawa S., Russell D.S., Duman R.S. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
42. Stanfield A.C., Moorhead T.W., Job D.E., McKirdy J., Sussmann J.E., Hall J., Giles S., Johnstone E.C., Lawrie S.M., McIntosh A.M. Structural abnormalities of ventrolateral and orbitofrontal cortex in patients with familial bipolar disorder. Bipolar Disord. 2009, 11:135-144.
43. Strakowski S.M., Delbello M.P., Adler C.M. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol. Psychiatry 2005, 10:105-116.
44. Szasz B.K., Mike A., Karoly R., Gerevich Z., Illes P., Vizi E.S., Kiss J.P. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol. Psychiatry 2007, 62:1303-1309.
45. Szymczyk G., Zebrowska-Lupina I. Influence of antiepileptics on efficacy of antidepressant drugs in forced swimming test. Pol. J. Pharmacol. 2000, 52:337-344.
46. Tekin S., Cummings J.L. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J. Psychosom. Res. 2002, 53:647-654.
47. Tomasiewicz H.C., Mague S.D., Cohen B.M., Carlezon W.A. Behavioral effects of short-term administration of lithium and valproic acid in rats. Brain Res. 2006, 1093:83-94.
48. Vazquez-Palacios G., Bonilla-Jaime H., Velazquez-Moctezuma J. Antidepressant-like effects of the acute and chronic administration of nicotine in the rat forced swimming test and its interaction with fluoxetine [correction of flouxetine]. Pharmacol. Biochem. Behav. 2004, 78:165-169.
49. Versace A., Almeida J.R., Hassel S., Walsh N.D., Novelli M., Klein C.R., Kupfer D.J., Phillips M.L. Elevated left and reduced right orbitomedial prefrontal fractional anisotropy in adults with bipolar disorder revealed by tract-based spatial statistics. Arch. Gen. Psychiatry 2008, 65:1041-1052.
50. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2001, 2:343-351.
51. Zhang Y., Gu F., Chen J., Dong W. Chronic antidepressant administration alleviates frontal and hippocampal BDNF deficits in CUMS rat. Brain Res. 2010.